Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bong, Jun Woo | - |
dc.contributor.author | Ju, Yeonuk | - |
dc.contributor.author | Seo, Jihyun | - |
dc.contributor.author | Lee, Jung Ae | - |
dc.contributor.author | Kang, Sang Hee | - |
dc.contributor.author | Lee, Sun Il | - |
dc.contributor.author | Min, Byung Wook | - |
dc.date.accessioned | 2021-11-20T04:40:15Z | - |
dc.date.available | 2021-11-20T04:40:15Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 2288-6575 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128073 | - |
dc.description.abstract | Purpose: Neoadjuvant chemoradiotherapy has been accepted as a standard treatment for stage II-III rectal cancer. This study aimed to evaluate the clinical characteristics of patients who underwent neoadjuvant chemoradiotherapy for rectal cancer and effects on overall survival (OS) of neoadjuvant chemoradiotherapy in South Korea. Methods: Patients who underwent curative resection for rectal cancer from 2014 to 2016 were retrospectively reviewed from the database of the National Quality Assessment program in South Korea. Patients were categorized into the upfront surgery group and neoadjuvant chemoradiotherapy group. We evaluated factors associated with the administration of neoadjuvant chemoradiotherapy and its effects on OS. Inverse probability of treatment weighting was performed to account for baseline differences between subgroups. Results: A total of 6,141 patients were categorized into the upfront surgery group (n = 4,237) and neoadjuvant chemoradiotherapy group (n = 1,904). The neoadjuvant chemoradiotherapy was more frequently administered to male, midrectal cancer, and younger patients. In the neoadjuvant chemoradiotherapy group, old age, underweight, and pathologic stage were significant risk factors of OS, and male sex, the level of tumor and clinical stages were not associated with OS. After adjustment, the OS of the neoadjuvant chemoradiotherapy group followed the OS of the upfront surgery group of the same pathologic stage. Conclusion: Male sex and the level of tumor were not related to the OS of rectal cancer patients with neoadjuvant chemoradiotherapy. The OS of patients who underwent neoadjuvant chemoradiotherapy was decided by their pathologic stages regardless of clinical stages. [Ann Surg Treat Res 2021;100(5):282-290] | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SURGICAL SOCIETY | - |
dc.subject | PATHOLOGICAL STAGE | - |
dc.subject | RESECTION MARGIN | - |
dc.subject | III TRIAL | - |
dc.subject | SURVIVAL | - |
dc.subject | SURGERY | - |
dc.subject | CHEMORADIATION | - |
dc.subject | MULTICENTER | - |
dc.title | Clinical characteristics of rectal cancer patients with neoadjuvant chemoradiotherapy: a nationwide population-based cohort study in South Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Sang Hee | - |
dc.identifier.doi | 10.4174/astr.2021.100.5.282 | - |
dc.identifier.scopusid | 2-s2.0-85105555474 | - |
dc.identifier.wosid | 000648657600005 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL TREATMENT AND RESEARCH, v.100, no.5, pp.282 - 290 | - |
dc.relation.isPartOf | ANNALS OF SURGICAL TREATMENT AND RESEARCH | - |
dc.citation.title | ANNALS OF SURGICAL TREATMENT AND RESEARCH | - |
dc.citation.volume | 100 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 282 | - |
dc.citation.endPage | 290 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002710765 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | PATHOLOGICAL STAGE | - |
dc.subject.keywordPlus | RESECTION MARGIN | - |
dc.subject.keywordPlus | III TRIAL | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | CHEMORADIATION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | Neoadjuvant therapy | - |
dc.subject.keywordAuthor | Rectal neoplasms | - |
dc.subject.keywordAuthor | Survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.